Recent Updates
Recently added Catalysts
PHAR Positive Sentiment

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

Key Takeaway: Pharming Group N.V. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP of Investor Relations, will lead a Fireside Chat Q&A session on August 12. The company invites interested parties to schedule meetings with its management team during the conference.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pharming Group is actively engaging with investors.
  • Participation in a prominent conference enhances visibility.
  • Opportunity for one-on-one meetings with management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
9.3%
average across 4 past catalysts
Lead asset
Recombinant human C1 inhibitor
Phase 3 · Hereditary Angioedema

Full Press Release Details

Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46 th Annual Growth Conference in Boston on August 12-13, 2026.
Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST.
For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Canaccord Genuity representative.
About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.
For more information, visit www.pharming.com and find us on LinkedIn. For further public information, contact: Pharming Michael Levitan, VP Investor Relations and Capital Markets T: +1 (908) 705 1696 E: investor@pharming.com
Saskia Mehring, Head of Corporate Communications T: +31 6 28 32 60 41 E: media.relations@pharming.com

Media Relations Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming) E: JDeutsch@lyraadvisory.com

Frequently Asked Questions

When is the Canaccord Genuity conference?

The conference will take place on August 12-13, 2026.

Who will represent Pharming at the conference?

Michael Levitan, VP of Investor Relations, will represent Pharming.

What session will Michael Levitan participate in?

He will participate in a Fireside Chat Q&A session on August 12.

How can investors schedule meetings with Pharming's team?

Investors can contact Pharming's Investor Relations team for scheduling.

Last updated: Aug 4, 2026